从病理生理学到先进的关节内药物输送策略:解开类风湿性关节炎
Hemant Singh1, Aniruddha Dan2, Mukesh Kumar Kumawat3
1Biological Sciences and Engineering, Indian Institute of Technology, Gandhinagar, 382055, Gujarat, India; Department of Biology, Khalifa University, Main Campus, Abu Dhabi, 127788, United Arab Emirates.
Biomaterials
|November 20, 2023
概括
本综述探讨了针对类风湿性关节炎 (RA) 的基于生物材料的关节内药物递送系统 (IA-DDS). 这些先进的系统针对关节,提供可控的药物释放和降低全身毒性,以更好地管理RA.
科学领域:
- 生物材料科学 生物材料科学
- 类风湿病学 类风湿病学
- 药物输送系统 药物输送系统
背景情况:
- 风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,导致关节炎症和退化.
- 目前的RA治疗通常需要高的全身剂量,导致毒性和有效性有限.
- 了解RA的发病因子,推动了针对性治疗的发展.
研究的目的:
- 为了提供有关类风湿性关节炎 (RA) 病变的全面概述.
- 讨论基于生物材料的新型关节内药物递送系统 (IA-DDS) 的设计和开发.
- 巩固当前的知识并确定RA的IA-DD战略中的研究差距.
主要方法:
- 审查有关RA病变的现有文献.
- 对各种关节内药物递送系统 (IA-DDS) 的分析,包括纳米载体,微粒和水凝.
- 讨论生物材料在关节腔中有针对性和受控的药物释放策略.
主要成果:
- 关节内药物输送系统 (IA-DDS) 提供针对性向RA受影响的关节提供药物输送.
- 基于生物材料的IA-DDS可以控制药物释放,最大限度地减少全身暴露和毒性.
- 不同的IA-DDS平台,从单一到双障碍系统,显示RA治疗的希望.
结论:
- 基于生物材料的IA-DDS是改善类风湿性关节炎 (RA) 管理的有希望的策略.
- 通过IA-DDS进行有针对性的输送和受控释放可以克服全身药物管理的局限性.
- 对新的IA-DD策略的进一步研究对于推进RA治疗至关重要.
相关概念视频
Drug Delivery: Miscellaneous Routes
358
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
358
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Inflammatory Bowel Disease IV: Pharmacological Management
132
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
132
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
146
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
146
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Drug Distribution: Tissue Binding
2.7K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.7K


